At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 155 enrolled
Drug / intervention
Elagolix +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of NBI-56418 in Subjects With Endometriosis
In Brief
A Phase 2 clinical trial evaluating Elagolix and placebo for Endometriosis, Pain. Completed, enrolled 155 participants.
Detailed Summary
This study is designed to see how elagolix works compared to placebo in women with endometriosis and to see the effect, if any, on bone mineral density.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEndometriosis, Pain
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartFeb 2008
First PostedFeb 2008
Primary CompletionApr 2009
Study CompletionAug 2009
TodayJul 2026
First PostedFeb 21, 2008
Enrollment StartFeb 19, 2008
Primary CompletionApr 20, 2009
Study CompletionAug 28, 2009
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 18.4 years ago
Interventions
Elagolixdrug
Elagolix tablets administered orally
placebodrug
Placebo tablet administered orally